Accepted Manuscript

Synthesis and bioactivity evaluation of 2,3-diaryl acrylonitrile derivatives as potential anticancer agents

Jun Ma, Jiajun Li, Yu-Shun Tian

PII:	S0960-894X(16)31167-2
DOI:	http://dx.doi.org/10.1016/j.bmcl.2016.11.025
Reference:	BMCL 24420
To appear in:	Bioorganic & Medicinal Chemistry Letters
Received Date:	20 August 2016
Revised Date:	9 October 2016
Accepted Date:	11 November 2016



Please cite this article as: Ma, J., Li, J., Tian, Y-S., Synthesis and bioactivity evaluation of 2,3-diaryl acrylonitrile derivatives as potential anticancer agents, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: http://dx.doi.org/ 10.1016/j.bmcl.2016.11.025

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Graphical Abstract

Thirty novel derivatives of 2,3-diaryl acrylonitrile were synthesized using TMSCN and TBAF, and evaluated for biological activity. Preliminary investigations of antitumor activity *in vitro* showed that most of the synthesized compounds have significant antiproliferative effects on human cancer cell lines, such as BEL-7402, HeLa, and HCT116 with IC₅₀ values in the range of 0.13–60.23 μ M without significant toxic effects on the non-cancerous human liver cell line L-02. In particular, compounds **4d** and **4p** were found to be the most potent against HeLa (4.20 μ M) and HCT116 cells (0.13 μ M), respectively, with superior or similar *in vitro* efficacy to that of the broad-spectrum anticancer drug taxol.



Download English Version:

https://daneshyari.com/en/article/5155951

Download Persian Version:

https://daneshyari.com/article/5155951

Daneshyari.com